Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
09 août 2023 12h30 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
10 juil. 2023 15h59 HE
|
Interpace Biosciences, Inc.
Q2 Revenue of $11 million; a 49.1% increase year-over-year and 12.2% better than Q1; highest quarter in history1st Half Revenue $20.9 million; 36.1% improvement over 1st Half 2022Q2 Test volume up...
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
05 juin 2023 16h05 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS)...
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
12 mai 2023 16h05 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting...
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
27 mars 2023 16h05 HE
|
Interpace Biosciences, Inc.
●Q4 Revenue of $8.3 million ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
20 oct. 2022 16h28 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
01 sept. 2022 17h18 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant...
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
31 août 2022 17h30 HE
|
Interpace Biosciences, Inc.
Interpace Transitions to focused Molecular Diagnostics BusinessDisposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 ...
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
15 août 2022 16h05 HE
|
Interpace Biosciences, Inc.
●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
16 mai 2022 16h15 HE
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...